Proactive Investors - Run By Investors For Investors

Circassia's AirNOvent drug a step closer to market with FDA pre-submission meeting

Circassia Pharmaceuticals PLC (LON:CIR) CEO Steve Harris tells Proactive London's Andrew Scott their partner, AIT Therapeutics Inc. has successfully completed a pre-submission meeting with the US FDA for the ventilator-compatible nitric oxide product AirNOvent.

AIT anticipates submitting a Premarket Approval application (PMA) for AirNOvent in the second quarter of 2019 for use in the treatment of hypoxic respiratory failure associated with persistent pulmonary hypertension of the newborn (PPHN).

Circassia intends launching the product in the first half of 2020, once approved.

 
Meet Manolete Partners PLC, Arkle Resources PLC, Royal Road Minerals and Neo Lithium Corp at our event, London , 04 April 2019. Register here »
View full CIR profile View Profile

Circassia Pharmaceuticals Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use